Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Argus Health
Covington
Accenture
Citi
Harvard Business School
Federal Trade Commission
US Department of Justice

Generated: November 13, 2018

DrugPatentWatch Database Preview

Assertio Company Profile

« Back to Dashboard

What is the competitive landscape for ASSERTIO, and when can generic versions of ASSERTIO drugs launch?

ASSERTIO has three approved drugs.

There are nineteen US patents protecting ASSERTIO drugs.

Summary for Assertio
US Patents:19
Tradenames:3
Ingredients:2
NDAs:3

Drugs and US Patents for Assertio

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Assertio GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 BX RX Yes Yes 6,723,340 ➤ Try a Free Trial Y ➤ Try a Free Trial
Assertio GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 BX RX Yes Yes 7,438,927 ➤ Try a Free Trial ➤ Try a Free Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes 8,927,604 ➤ Try a Free Trial ➤ Try a Free Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes 9,827,197 ➤ Try a Free Trial Y ➤ Try a Free Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes 8,097,651 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Assertio GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 BX RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Assertio

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Assertio GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 6,635,280 ➤ Try a Free Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 6,974,595 ➤ Try a Free Trial
Assertio GRALISE gabapentin TABLET;ORAL 022544-001 Jan 28, 2011 6,635,280 ➤ Try a Free Trial
Assertio GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 6,340,475 ➤ Try a Free Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 7,482,377 ➤ Try a Free Trial
Assertio GRALISE gabapentin TABLET;ORAL 022544-001 Jan 28, 2011 6,340,475 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ASSERTIO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Potassium Oral Solution (Sachet) 50 mg ➤ Subscribe 2011-01-24
➤ Subscribe Capsules 25 mg ➤ Subscribe 2012-11-14
➤ Subscribe Tablets 300 mg and 600 mg ➤ Subscribe 2011-10-31

International Patents for Assertio Drugs

Country Document Number Estimated Expiration
Japan 2013224324 ➤ Try a Free Trial
China 104856959 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 2006133954 ➤ Try a Free Trial
Peru 00742007 ➤ Try a Free Trial
South Africa 200200741 ➤ Try a Free Trial
Portugal 1890680 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Dow
Federal Trade Commission
Covington
Merck
Fuji
McKesson
Accenture
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.